SCHEMBL19928682

SCHEMBL19928682

CCC(C)(CC)OC1C(C(=O)O)OC(OC2C(O)C(CO)OC(C(C)(C)CC)C2NC(C)=O)C(O)C1O

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LGALS3 P17931 6/20 0.42
▸ LGALS8 O00214 1/20 0.42
▸ LGALS4 P56470 1/20 0.42
▸ MAPK1 P28482 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ THRB P10828 1/20 0.40
▸ MDK P21741 2/20 0.38
▸ BDNF P23560 2/20 0.38
▸ PTN P21246 1/20 0.38
▸ FGF1 P05230 1/20 0.38
▸ CD69 Q07108 1/20 0.38
▸ CHIA Q9BZP6 1/20 0.36
▸ LGALS1 P09382 1/20 0.36
▸ LGALS7; LGALS7B P47929 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ LGALS9 O00182 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19221227 0.93 LGALS3 (0.42) LGALS3LGALS8LGALS4MAPK1ALDH1A1
SCHEMBL21316642 0.93 LGALS3 (0.42) LGALS3LGALS8LGALS4MAPK1ALDH1A1
SCHEMBL22472735 0.93 LGALS3 (0.42) LGALS3LGALS8LGALS4MAPK1ALDH1A1
SCHEMBL20122304 0.93 LGALS3 (0.42) LGALS3LGALS8LGALS4MAPK1ALDH1A1
SCHEMBL16269841 0.93 LGALS3 (0.42) LGALS3LGALS8LGALS4MAPK1ALDH1A1
SCHEMBL20291137 0.90 LGALS3 (0.45) LGALS3LGALS8LGALS4MAPK1ALDH1A1
SCHEMBL25964185 0.90 MAPK1 (0.45) LGALS3LGALS8LGALS4MAPK1ALDH1A1
SCHEMBL22598693 0.89 MDK (0.45) LGALS3LGALS8LGALS4MAPK1ALDH1A1
SCHEMBL24121225 0.87 LGALS3 (0.39) LGALS3LGALS8LGALS4MAPK1ALDH1A1
SCHEMBL21316636 0.86 ALDH1A1 (0.42) LGALS3LGALS8LGALS4MAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10398636-B2 Deuterium-enriched hyaluronan Deuteria Biomaterials (US) 2019-09-03 — — US disclosed
US-10307362-B2 Dermal injectable sterile composition Teoxane SA (CH) 2019-06-04 — — US disclosed
US-20180140530-A1 DERMAL INJECTABLE STERILE COMPOSITION TEOXANE (CH) 2018-05-24 — — US disclosed
US-9907739-B2 Dermal injectable sterile composition TEOXANE (CH) 2018-03-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180140530-A1 DERMAL INJECTABLE STERILE COMPOSITION SRM, CD44, SMS LGALS3 1652/4885LGALS8 2612/4885LGALS4 2314/4885
US-10398636-B2 Deuterium-enriched hyaluronan DOHH, CD44, HDHD5 LGALS3 521/4885LGALS8 658/4885LGALS4 424/4885
US-10307362-B2 Dermal injectable sterile composition SRM, CD44, SMS LGALS3 1605/4885LGALS8 2575/4885LGALS4 2264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback